A potential antitumor peptide therapeutic derived from antineoplastic urinary protein

• Published in: Peptides (New York, N.Y. : 1980) N.Y. : 1980), 2004-04, Vol.25 (4), p.543-549
• Main Authors: Hehir, Kathleen M, Baguisi, Alexander, Pennington, Sarah E, Bates, Janna M, DiTullio, Paul A
• Format: Article
• Language: English
• Subjects: Angiogenesis; Animals; Antigens, Ly - administration & dosage; Antineoplastic urinary protein; ANUP; Biological and medical sciences; CAM; Chick Embryo; Cost of Illness; Female; Fundamental and applied biological sciences. Psychology; HeLa Cells; Humans; Mice; Mice, Nude; Neoplasms, Experimental - blood supply; Neoplasms, Experimental - drug therapy; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - pathology; Peptides - administration & dosage; Urokinase-Type Plasminogen Activator - administration & dosage; Vertebrates: endocrinology
• ISSN: 0196-9781; 1873-5169
• DOI: 10.1016/j.peptides.2004.02.003

New therapies in cancer treatment are focusing on multifaceted approaches to starve and kill tumors utilizing both antiangiogenic and chemotherapeutic compounds. Antineoplastic Urinary Protein (ANUP), a 32 kDa protein normally secreted in human urine, has been previously described as a molecule possessing both antiproliferative and antiangiogenic activities. Two synthetic peptides complimentary to the N-terminus of ANUP were designed to test their ability to reproduce these beneficial effects but ultimately to provide a more useful small molecule therapeutic. The results show that the peptides reduced tumor burden by up to 70% in a nude mouse model and demonstrated the ability to inhibit blood vessel formation in a chick chorioallantoic membrane assay (CAM).